Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model





) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole was unchanged today. By the end of trading, Sanofi fell 52 cents (-1.3%) to $40.64 on light volume. Throughout the day, 1.9 million shares of Sanofi exchanged hands as compared to its average daily volume of 3.5 million shares. The stock ranged in price between $40.46-$40.81 after having opened the day at $40.71 as compared to the previous trading day's close of $41.16. Other companies within the Health Care sector that declined today were:

Response Genetics



), down 11.6%,

Arrhythmia Research Technology



), down 9.3%,



Scroll to Continue

TheStreet Recommends


), down 8.9%, and

Bio-Reference Labs



), down 8.4%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Sanofi, together with its subsidiaries, researches, develops, manufactures, and markets healthcare products worldwide. Sanofi has a market cap of $110.19 billion and is part of the


industry. The company has a P/E ratio of 22.3, above the average drugs industry P/E ratio of 15 and above the S&P 500 P/E ratio of 17.7. Shares are up 13.7% year to date as of the close of trading on Wednesday. Currently there are six analysts that rate Sanofi a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Sanofi as a


. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, expanding profit margins, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care